Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two casesDenise Jaworsky, Courtney Thompson, Mark H Yudin, Ari Bitnun, Jason Brophy, Lindy Samson, Tony Antoniou, Mona R Loutfy
Corresponding author name: Mona R Loutfy
Corresponding author e-mail: firstname.lastname@example.org
Citation: Antiviral Therapy 2010; 15:677-680
Date published online: 11 June 2010
Background: Although antiretroviral therapy during pregnancy is associated with significant reductions in the risk of vertical transmission of HIV, attainment of this outcome in highly treatment-experienced pregnant women might be complicated by the lack of active drugs available to assemble a potent regimen. The recent licensing and availability of darunavir, etravirine and raltegravir has broadened management options available for highly treatment-experienced patients. However, data on their safety and efficacy in preventing vertical transmission are limited.
Methods: A retrospective chart review of two cases describing obstetrical, infant and treatment outcomes associated with the use of regimens that include darunavir and etravirine with or without raltegravir during pregnancy was conducted.
Results: We document two cases of pregnant HIV-positive women treated with antiretroviral therapy including darunavir, etravirine and raltegravir. Vertical transmission was averted and no congenital anomalies were observed.
Conclusions: In the absence of human development toxicity data for these agents, these cases provide preliminary anecdotal data on their safety during pregnancy. Although the outcomes of these cases are reassuring, additional studies and registries are required to establish the safety and efficacy of these agents during pregnancy.